首 页
医药产品
医保药品
中标目录
医药招标
数据中心
医学资料
医药新闻
医药展会
OTC药品
保健品
医疗器械
处方药
专科药
中医药
器械中标目录
药品批发行情
求购信息
医药下载
药价简讯
当前位置:药药网 / 数据中心 / 临床注释,变异和临床注释数据
曲马多
临床注释ID
1451155020
药物名称(英)
tramadol
变异单倍型
CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*41
基因
CYP2D6
证据级别
1A
水平覆盖
水平修饰符
Tier 1 VIP
表现型类别(英)
Metabolism/PK
表现型类别
代谢/PK
分数
227.1875
PMID计数
29
计数的证据
43
表现型
表现型(英)
最新日期
2021-10-28
URL
https://www.pharmgkb.org/clinicalAnnotation/1451155020
专业人口(英)
Pediatric
专业人口
儿科
临床等位基因
id
等位基因
注释文本
118
*41
The CYP2D6*41 allele has been assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients carrying the *41 allele in combination with a decreased or no function allele may have decreased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *41 allele in combination with an increased function allele may have increased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tramadol metabolism.
117
*17
The CYP2D6*17 allele has been assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients carrying the *17 allele in combination with a decreased or no function allele may have decreased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *17 allele in combination with an increased function allele may have increased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tramadol metabolism.
116
*10
The CYP2D6*10 allele has been assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the *10 allele in combination with a decreased or no function allele may have decreased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *10 allele in combination with a normal function allele or an increased function allele with an activity value of 2 may have similar metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *10 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tramadol metabolism.
115
*9
The CYP2D6*9 allele has been assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients carrying the *9 allele in combination with a normal, decreased or no function allele may have decreased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *9 allele in combination with an increased function allele may have increased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tramadol metabolism.
114
*6
The CYP2D6*6 allele has been assigned as a no function allele by CPIC. Patients carrying the *6 allele in combination with with a decreased, normal or no function allele may have decreased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *6 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tramadol metabolism.
113
*5
The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with with a decreased, normal or no function allele may have decreased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tramadol metabolism.
112
*4
The CYP2D6*4 allele has been assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with with a decreased, normal or no function allele may have decreased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tramadol metabolism.
111
*3
The CYP2D6*3 allele has been assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with a decreased, normal or no function allele may have decreased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tramadol metabolism.
110
*2
The CYP2D6*2 allele is assigned as a normal function allele by CPIC. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of tramadol as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of tramadol as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25 but increased metabolism of tramadol as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tramadol metabolism.
109
*1xN
The CYP2D6*1xN alleles (*1x2 and *1x鈮?) are assigned as increased function alleles by CPIC. Patients carrying a *1xN allele in combination with a normal or increased function allele or a decreased function allele with an activity value of 0.5 may have increased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *1xN allele with an activity value of 3 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may also have increased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *1xN allele with an activity value of 2 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may have similar metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tramadol metabolism.
108
*1
The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of tramadol as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of tramadol as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25 but increased metabolism of tramadol as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tramadol metabolism.
临床证据
id
证据的ID
总结
14698
1451229440
CYP2D6 *10/*10 is associated with increased exposure to tramadol in healthy individuals as compared to CYP2D6 *1 + *2.
14697
1451208380
CYP2D6 *3/*4 + *4/*4 (assigned as poor metabolizer phenotype) are associated with decreased concentrations of o-desmethyltramadol as compared to CYP2D6 *1/*1 + *1/*4 + *1/*6 + *1/*10 + *4/*10 + *10/*10.
14696
1451207940
CYP2D6 *1/*1xN (assigned as ultrarapid metabolizer phenotype) is associated with increased clearance of tramadol in healthy individuals as compared to CYP2D6 *1/*1 + *1/*4 + *1/*41 (assigned as normal metabolizer phenotype) .
14695
1451157920
CYP2D6 *4/*4 (assigned as poor metabolizer genotype phenotype) is associated with decreased metabolism of tramadol as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*6 + *1/*9 + *4/*9 (assigned as normal metabolizer genotype phenotype) .
14694
1451157820
CYP2D6 *1/*1xN is associated with increased metabolism of tramadol in infants as compared to CYP2D6 *1/*1.
14579
1183618008
CYP2D6 *3 is associated with decreased tramadol metabolism when exposed to tramadol as compared to CYP2D6 *1.
14578
1183617999
CYP2D6 *4 is associated with decreased tramadol metabolism when exposed to tramadol as compared to CYP2D6 *1.
14577
1451230640
CYP2D6 poor metabolizers and intermediate metabolizers are associated with increased concentrations of n-desmethyltramadol in people with Neoplasms and Pain as compared to CYP2D6 normal metabolizers.
14576
1451230620
CYP2D6 poor metabolizers and intermediate metabolizers are associated with decreased concentrations of o-desmethyltramadol in people with Neoplasms and Pain as compared to CYP2D6 normal metabolizers.
14575
1451207900
CYP2D6 poor metabolizer is associated with increased exposure to tramadol as compared to CYP2D6 intermediate metabolizer and normal metabolizer.
14574
1451155820
CYP2D6 poor metabolizer phenotype is associated with decreased metabolism of tramadol in healthy individuals as compared to CYP2D6 normal metabolizer phenotype.
14573
1451155560
CYP2D6 poor metabolizer is associated with decreased metabolism of tramadol in healthy individuals as compared to CYP2D6 normal metabolizer.
14572
1451153020
CYP2D6 poor metabolizer phenotype is associated with decreased metabolism of tramadol in healthy individuals as compared to CYP2D6 normal metabolizer phenotype.
14571
1451134168
CYP2D6 poor metabolizers and intermediate metabolizers are associated with decreased concentrations of o-desmethyltramadol in healthy individuals as compared to CYP2D6 normal metabolizers.
14570
1451134163
CYP2D6 poor metabolizers and intermediate metabolizers are associated with increased concentrations of tramadol in healthy individuals as compared to CYP2D6 normal metabolizers.
14569
1449752878
CYP2D6 poor metabolizer is associated with increased concentrations of o-desmethyl-tramadol in people with Low Back Pain and Osteoarthritis as compared to CYP2D6 normal metabolizer.
14568
1449752869
CYP2D6 ultrarapid metabolizer is associated with increased concentrations of o-desmethyl-tramadol in people with Low Back Pain or Osteoarthritis as compared to CYP2D6 normal metabolizer.
14567
1449162774
CYP2D6 poor metabolizer genotype is not associated with exposure to o-desmethyl-tramadol or tramadol as compared to CYP2D6 normal metabolizer genotype.
14566
1449154915
CYP2D6 deficiency is associated with decreased exposure to o-desmethyl-tramadol in infants with Pain.
14565
1446896368
CYP2D6 ultrarapid metabolizer genotype is associated with increased metabolism of tramadol.
14564
1183684661
CYP2D6 normal metabolizer genotype is associated with increased metabolism of tramadol in healthy individuals as compared to CYP2D6 poor metabolizer genotype.
14563
1183684657
CYP2D6 ultra-metabolizer genotype is associated with increased metabolism of tramadol in healthy individuals as compared to CYP2D6 poor metabolizer genotype.
14562
1183684653
CYP2D6 ultra-metabolizer genotype is associated with increased likelihood of nausea when treated with tramadol in healthy individuals as compared to CYP2D6 normal metabolizer genotype.
14561
1183684640
CYP2D6 ultra-metabolizer genotype is associated with increased metabolism of tramadol in healthy individuals as compared to CYP2D6 normal metabolizer genotype.
14560
1183617989
CYP2D6 poor metabolizer is associated with decreased metabolism of tramadol and decreased response to tramadol when treated with tramadol as compared to CYP2D6 normal metabolizer.
14559
PA166104959
Annotation of DPWG Guideline for tramadol and CYP2D6
14558
PA166228101
Annotation of CPIC Guideline for tramadol and CYP2D6
14502
1451565700
CYP2D6 *1/*5 + *1/*10 + *2/*5 + *2/*10 + *5/*10 + *10/*10 are associated with increased concentrations of n-desmethyltramadol in people with Head and Neck Neoplasms as compared to CYP2D6 *1/*1 + *1/*2.
14501
1451552540
CYP2D6 *1/*4 + *1/*9 (assigned as intermediate metabolizer genotype phenotype) are associated with increased exposure to tramadol in healthy individuals as compared to CYP2D6 *1/*1 (assigned as normal metabolizer genotype phenotype) .
14500
1451229680
CYP2D6 *4/*4 + *4/*5 (assigned as poor metabolizer phenotype) are associated with decreased exposure to n,o-didesmethyltramadol or o-desmethyltramadol in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2 + *1/*3 + *1/*4 + *1/*5 + *1/*9 + *1/*35 + *1/*41 + *2/*5 + *2/*35 + *2/*41 + *4/*35 + *4/*41 (assigned as intermediate metabolizer and normal metabolizer phenotype) .
14499
1451229484
CYP2D6 *5/*5 + *10/*10 are associated with decreased concentrations of n,o-didesmethyltramadol or o-desmethyltramadol in healthy individuals as compared to CYP2D6 *1 + *2.
14410
1451157780
CYP2D6 *1/*3 + *1/*4 + *1/*5 + *1/*6 + *3/*3 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*41 are associated with decreased metabolism of tramadol in infants as compared to CYP2D6 *1/*1.
14409
1451156620
CYP2D6 *1/*1xN is associated with decreased concentrations of tramadol in healthy individuals as compared to CYP2D6 *1/*2 + *2/*4.
14408
1451155780
CYP2D6 *4/*4 + *4/*6 are associated with decreased metabolism of tramadol in healthy individuals as compared to CYP2D6 *1/*1.
14407
1451154280
CYP2D6 *1/*4 + *1/*5 + *1/*9 + *1/*10 + *4/*10 + *5/*10 + *10/*10 + *10/*17 are associated with decreased clearance of tramadol as compared to CYP2D6 *1/*1.
14406
1183680395
CYP2D6 *4/*4 is associated with decreased clearance of tramadol in healthy individuals as compared to CYP2D6 *1/*1.
14405
1183678588
CYP2D6 *17 is associated with decreased clearance of tramadol as compared to CYP2D6 *1.
14404
1183678578
CYP2D6 *10 is associated with decreased clearance of tramadol as compared to CYP2D6 *1.
14403
1183618142
CYP2D6 *2/*2 is not associated with decreased tramadol clearance in chinese volunteers when treated with tramadol in healthy individuals as compared to CYP2D6 *1/*1.
14402
1183618134
CYP2D6 *2/*10 is associated with decreased tramadol clearance in chinese volunteers when treated with tramadol in healthy individuals as compared to CYP2D6 *1/*1.
14401
1183618125
CYP2D6 *10/*10 is associated with decreased tramadol clearance in chinese volunteers when treated with tramadol in healthy individuals as compared to CYP2D6 *1/*1.
14400
1183618024
CYP2D6 *4/*4 is associated with decreased tramadol metabolism and response when treated with tramadol in healthy individuals as compared to CYP2D6 *1/*1.
14399
1183618016
CYP2D6 *6 is associated with decreased tramadol metabolism when exposed to tramadol as compared to CYP2D6 *1.
临床病史
id
类型
评论
208
Update
Minor edits to phenotype descriptions
207
Update
Rewrote phenotype descriptions and added CPIC guideline
206
Update
Added PMID 30051214 to evidence
205
Update
Added PMID 29992026 to evidence
204
Update
Added PMID 29524157 to evidence
203
Update
Added PMID 29196917 to evidence
202
Update
Added PMID 26926096 to evidence and updated phenotype descriptions.
201
Update
Added PMID 25560051 to evidence and updated phenotype descriptions
200
Update
Added PMID 24968714 to evidence
199
Update
Added PMID 18520597 to evidence and updated phenotype descriptions.
77
Update
Added PMID 33131142 to evidence
76
Update
Added PMID 32538291 to evidence and updated phenotype description for *9.
75
Update
Added DPWG guideline as evidence
74
Update
CA score added as part of scoring system release. LOE assigned following curator review.
73
Update
Minor edits to phenotype descriptions
39
Update
Added PMID 18317231 to evidence and added phenotype description for the *41 allele
38
Update
Added PMID 17667796 to evidence and updated phenotype descriptions
37
Update
Added PMID 17175164 to evidence
36
Update
Added PMID 16763825 to evidence
35
Update
Added PMID 15906019 to evidence
34
Create
Created
最新招商产品
更多>>
网站地图
-
网站开发
-
网站简介
-
会员服务
-
法律声明
-
联系我们
-
药品招商频道
-
药品信息排行
-
2018年版国家基本药物目录
-
意见反馈
免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:
国家药品监督管理局
|
国家中医药管理局
|
SDA药品评审中心
|
医加医疗器械
|
膏药生产厂家
|
爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究 客服热线:0575-83552251 / 13754370441 QQ客服:
浙ICP备16010490号-2
增值电信业务经营许可证:
浙B2-20220931
互联网药品信息服务资格证书编号:
(浙)-经营性2023-0215
浙公网安备:33068302000535
医药代理商群1:
医药代理商群2:
医药代理商群3: